[1] MICHAEL J, SLOWEY M D, CONCORD N C. Polycysic ovary syndrom:New perspective on old promble, 2001(2)
[2] BRINGER J, RAINGEARD I, RENARD E. Insulin sensitivity and polycystic ovarian syndrome, 2001(2)
[3] van DAM E W, ROELFSEMA F, VELDHUIS J D. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS, 2002(4)
[4] FRUZZETTI F, BERRIS C, PARRINI D. Treatment of Hirsutism comparisons between different antiandrogens with central and peripheral effects. 1999(3). doi:10.1016/S0015-0282(98)00486-5
[5] SCHEEN A J, JANDRAIN B J, HUMBLET D M. Effect of a 1-year treatment with a low dose combined oral contraceptive containing eithinyl estradial and cyproterone acetate anglucose and insulin metabolism, 1993
[6] AJOSSA S, GUERRIERO S, PAOLELTI A M. The antiandrogenic effect of fluta mide improves uterine perfusion in women with polycystic ovarian syndrome, 2002(6)
[7] ITSKOVITZ-ELDOR J, LEVRON J, KOL S. Use of gonadotropin-releasing hormone agonist to cause ovulation and prevent the ovarian hyperstimulation syndrome. 1993. doi:10.1097/00003081-199309000-00026
[8] BALASCH J, TUR R, CREUS M. Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy, 1994
[9] MOGHETTI P, CASTELLO R, NEGRI C. Metformin effects on clinical features,endocrine and metabolic profiles,and insulin sensitivity in polycystic ovary syndrome:a randomized,double-blind,placebo-controlled 6-month trial,followed by open,long-term clinical evaluation, [外文会议] 2000
[10] GLUECK C J, WANG P, GOLDENBERG N. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. 2002(11). doi:10.1093/humrep/17.11.2858
[11] GLUECK C J, WANG P, KOBOYASHI S. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. 2002(3)
[12] FULGHESU A M, MARIO-CIAMPELLI M, GIUSEPPE-MUZJ G. N-Acetyl-cysteine treatment improves insuline sensitivity in women with polycystic ovary syndrome. 2002(6)
[13] GIOTTA L, DELEO V, FARRINA M. Endocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia. 2001(1)
[14] GIOTTA L, DELEO V, GALVANI F. Endiocrine and metabolic effects of octreotide,a so matostatin analogue,in lean PCOS patients with either hyperinsulinaemia or lean nor moininsulinaemia, 1999(12)
[15] NESTLER J E, JAKUBOWICZ D J, REAMER P. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. 1999(17). doi:10.1056/NEJM199904293401703
[16] FULGHESU A M, APA R, BELOSI C. Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in an ovulatory patients with polycystic ovary syndrome:a safe and more effective treatment. 2001(5)
[17] YILDIRIM M, NOYAN V, BULENT T M. Ovarian wedge resection by minilaparatomy in infertile patients with polycystic ovarian syndrome:a new technique, 2003(1)
[18] RAMZY A M, AI-INANY H, ABOULFOUTOUH I. Ultrasonographic guided ovarian stroma hydrocoagulation for ovarian stimulation in polycystic ovary syndrome. 2001(11) |
